Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344885 | 0.91 | RECQL (0.45) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2885658 | 0.85 | MEN1 (0.49) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2885600 | 0.84 | MEN1 (0.45) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2883282 | 0.83 | KDM4E (0.43) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2885988 | 0.83 | KMT2A (0.42) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2886626 | 0.82 | MEN1 (0.43) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2885659 | 0.81 | AGTR1 (0.46) | RECQLMEN1KMT2AAGTR1LMNA | |
| SCHEMBL2885775 | 0.80 | KMT2A (0.45) | RECQLMEN1KMT2APTGDR2AGTR1 | |
| SCHEMBL2886814 | 0.80 | MEN1 (0.44) | MEN1KMT2APTGDR2AGTR1LMNA | |
| SCHEMBL2883359 | 0.79 | SMN1; SMN2 (0.42) | MEN1KMT2AAGTR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-2035429-A1 | FUSED [d]PYRIDAZIN-7-ONES | Cephalon, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | RECQL 1952/4885MEN1 2202/4885KMT2A 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.